ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,078.00
-0.21%
다우존스 지수
39,869.38
-0.10%
Bitcoin
65,454.55
0.33%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) 뉴스

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LIFE
일자시간출처헤드라인심볼기업
2024/05/1520:00GlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
2024/05/1421:00GlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
2024/05/0621:00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
2024/05/0305:00GlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
2024/04/0121:00GlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
2024/03/1505:00GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
2024/02/2822:00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
2024/02/2122:00GlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
2024/02/0710:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/02/0710:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/2922:00GlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
2024/01/1822:00GlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
2024/01/1009:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/1009:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/0302:21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
2023/12/1308:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2023/11/2114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
2023/11/1406:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2023/11/1322:00GlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
2023/11/1007:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:00GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
2023/11/0121:00GlobeNewswire Inc.aTyr Pharma to Present at November Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
2023/10/3121:00GlobeNewswire Inc.aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDNASDAQ:LIFEaTyr Pharma Inc
2023/09/2622:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
2023/09/1121:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
2023/09/1121:00GlobeNewswire Inc.aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesNASDAQ:LIFEaTyr Pharma Inc
2023/08/2421:00GlobeNewswire Inc.aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LIFEaTyr Pharma Inc
 검색 관련기사 보기:NASDAQ:LIFE

최근 히스토리

BIT
UI963C
Unicredit Bank
NYSE
FSL.B
Freescale
COIN
MOGXUST
Mogu Token
LSE
3ZM
3x Zoom
COIN
MODXEUR
LSE
89ZM
Hsbc Bk. 26
BOV
BBASH450
BBASH450 Ex:19
BIT
GS0243
Goldman Sachs Finance
LSE
10CY
Hsbc Bk. 23
LATK
JCTETH
Japan Content Token
COIN
DTEPEUR
Decoin
LSE
SV02
Citi Fun 28
EU
AFDEB
Agence Francaise de Deve...
NYSE
BCS-A.CL
ASX
RIOLOG
LSE
BB31
Aigt.fin 30
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유